BTK

Cat. No.

A34488

CAS No.

1952316-43-6

(R)-Acalabrutinib

Synonyms: (R)-ACP-196

(R)-Acalabrutinib is a specific inhibitor of Bruton’s tyrosine kinase (BTK), a critical protein involved in B-cell receptor signaling. This compound serves as a valuable tool for research applications in hematological malignancies, particularly in the study of B-cell functions and the development of targeted therapies for conditions such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. Its high selectivity for BTK allows for detailed investigations into BTK-mediated pathways and potential therapeutic interventions.

Cat. No.

A34489

CAS No.

1374240-01-3

BTK-IN-19

BTK-IN-19 is a reversible Bruton's tyrosine kinase (BTK) inhibitor with an IC50 of less than 0.001 μM. This compound demonstrates potent inhibitory activity against BTK, making it a valuable tool for studying B-cell signaling pathways. BTK-IN-19 is applicable in research focused on various hematological malignancies and autoimmune diseases, contributing to the understanding of therapeutic strategies targeting BTK.

Cat. No.

A34490

CAS No.

2883232-92-4

BTK-IN-16

BTK-IN-16 is a dual inhibitor targeting Bruton’s tyrosine kinase (BTK), specifically effective against both wild type and the C481S mutant, with IC50 values of 5.1 μM and 4.1 μM, respectively. This compound is crucial for research into autoimmune diseases and chronic lymphocytic leukemia, where BTK plays a significant role in disease progression. Its ability to inhibit both forms of BTK makes BTK-IN-16 a valuable tool for studying therapeutic strategies in these conditions.

Cat. No.

A34491

CAS No.

2563861-90-3

PROTAC BTK Degrader-3

PROTAC BTK Degrader-3 is a selective degrader targeting Bruton's tyrosine kinase (BTK) with a DC50 value of 10.9 nM for BTK degradation in Mino cells. This compound demonstrates significant biological activity and is applicable in research focusing on B-cell malignancies, particularly chronic lymphoid malignancies. Its mechanism of action offers potential pathways for therapeutic intervention in relevant disease models.

Cat. No.

A34492

CAS No.

1226872-27-0

BTK-IN-3

BTK-IN-3 is a selective inhibitor of Bruton's tyrosine kinase (BTK), a critical component in B-cell receptor signaling. This compound demonstrates significant biological activity by inhibiting BTK-mediated pathways, which are often implicated in various hematological malignancies. BTK-IN-3 is therefore utilized in research applications focused on cancer biology, particularly in the investigation of B-cell cancers and autoimmune disorders.

Cat. No.

A34494

CAS No.

2031255-23-7

Ibrutinib dimer

Ibrutinib dimer is a dimeric form of Ibrutinib, a selective and irreversible inhibitor of Bruton’s tyrosine kinase (Btk) with an IC50 of 0.5 nM. This compound serves as a valuable tool for studying Btk-mediated signaling pathways and its implications in various hematological malignancies. Researchers can utilize Ibrutinib dimer to investigate the effects of Btk inhibition in cellular models and to explore its potential therapeutic applications in cancer research.

Cat. No.

A34495

CAS No.

1807619-60-8

(Rac)-IBT6A hydrochloride

(Rac)-IBT6A hydrochloride is a racemic mixture of IBT6A, a byproduct of Ibrutinib. This compound acts as a selective, irreversible Bruton's tyrosine kinase (Btk) inhibitor with an IC50 of 0.5 nM, making it useful for studying Btk-mediated signaling pathways. It serves as a valuable reagent in the synthesis of Ibrutinib derivatives and adducts, facilitating research into therapeutic strategies for diseases such as B-cell malignancies.

Cat. No.

A34496

CAS No.

3114684-06-6

PROTAC BTK degrader-14

PROTAC BTK Degrader-14 is a targeted protein degrader that specifically degrades Bruton's tyrosine kinase (BTK) through the PROTAC mechanism of action. This compound is significant in cancer research, particularly for studies focused on malignancies where BTK plays a crucial role in signaling pathways. Its ability to effectively modulate BTK levels can provide insights into therapeutic strategies and disease mechanisms involving this key protein.

Cat. No.

A34497

CAS No.

1709786-35-5

BTK ligand 9

BTK Ligand 9 is a selective ligand for Bruton's tyrosine kinase (BTK), a critical regulator in B cell receptor signaling. This compound facilitates the development of PROTACs, specifically PROTAC DD-03-171, which are utilized in targeted protein degradation studies. Research applications include investigating the role of BTK in various hematological malignancies and exploring therapeutic strategies for B cell-related diseases.

Cat. No.

A34498

CAS No.

2662512-14-1

(R,R)-Birelentinib

Synonyms: (R,R)-DZD8586

(R,R)-Birelentinib is a potent Bruton's tyrosine kinase (BTK) inhibitor, achieving IC50 values of 0.7 nM for wild-type BTK and 0.86 nM for the C481S mutant. This compound effectively inhibits the self-phosphorylation of BTK, with an IC50 of 24.3 nM. (R,R)-Birelentinib demonstrates significant anti-proliferative effects against wild-type and C481S mutant HEK293 cells, making it valuable for research into drug-resistant B-cell malignancies.

Cat. No.

A34499

CAS No.

2377643-84-8

BTK degrader-1 intermediate

BTK Degrader-1 Intermediate is a key precursor in the synthesis of BTK Degrader-1, a potent molecule targeting Bruton's tyrosine kinase (BTK). This compound serves as an essential building block for developing antibody-drug conjugates (ADCs), enabling targeted therapy for diseases associated with BTK dysregulation. Researchers utilize BTK Degrader-1 Intermediate in drug development processes to explore innovative treatment strategies in oncology and immunology.

Cat. No.

A34500

CAS No.

845269-74-1

CGI 560

CGI 560 is a potent inhibitor of Bruton's tyrosine kinase (BTK), exhibiting an IC50 value of 400 nM. This compound plays a significant role in the modulation of B-cell receptor signaling pathways, making it a valuable tool for research in hematological malignancies and autoimmune diseases. Its ability to selectively inhibit BTK can aid in elucidating the mechanistic underpinnings of various B-cell-related disorders.

Cat. No.

A84666

CAS No.

3114078-55-3

BTK-IN-48

BTK-IN-48 is a potent inhibitor of Bruton's tyrosine kinase (BTK) with an IC50 of 1.14 μM. This compound effectively inhibits recombinant BTK and c-Src, demonstrating moderate activity against LCK, BMX/ETK, FLT3, and PIM1. BTK-IN-48 is valuable for research related to B-cell malignancies and autoimmune diseases, making it a useful tool for understanding the underlying mechanisms of these conditions.

Cat. No.

B18244

CAS No.

79-05-0

Propionamide

Propionamide is a saturated amide small molecule that serves as a useful tool in the mechanistic analysis of Bruton’s tyrosine kinase (BTK) covalent inhibitors. This compound can aid researchers in understanding the interactions and effects of BTK inhibition in various biological contexts, particularly in the study of hematological malignancies and immune response modulation. Its role in these pathways makes Propionamide valuable for further exploration of therapeutic strategies targeting BTK.

Cat. No.

B18349

CAS No.

330792-60-4

cis-KIN-8194

cis-KIN-8194 is the cis-isomer of KIN-8194, primarily targeting specific signaling pathways involved in cellular processes. This compound exhibits potent biological activity, contributing to research in the field of cancer biology and potential therapeutic applications. Its structural properties make it valuable for studying the effects of isomeric forms on enzyme modulation and cellular response.